Table 4.
The results of SUCRA in the sensitivity analysis.
| Treatment | 4-Week healing rate | 8-Week healing rate | ||||
|---|---|---|---|---|---|---|
| SUCRA | PrBest | MeanBank | SUCRA | PrBest | MeanBank | |
| Teg50 | 61.4 | 5.7 | 6.8 | 81.3 | 26.5 | 3.8 |
| Kev20 | 47.2 | 2 | 8.9 | 79.3 | 21.3 | 4.1 |
| Teg100 | 75 | 17.1 | 4.7 | 74.9 | 14.6 | 4.8 |
| Vpz20 | 66.9 | 1.6 | 6 | 73.7 | 2.2 | 4.9 |
| Ila10 | 75.8 | 4.1 | 4.6 | 71.7 | 2.5 | 5.3 |
| Vpz40 | 87.3 | 51.4 | 2.9 | 67.4 | 9.9 | 5.9 |
| Eso40 | 68.3 | 0.1 | 5.8 | 64.9 | 0.1 | 6.3 |
| Fex40 | 72.6 | 15.8 | 5.1 | 55.6 | 22.6 | 7.7 |
| Pan40 | 43.1 | 0 | 9.5 | 50.0 | 0 | 8.5 |
| Lan30 | 40.3 | 0 | 9.9 | 37.2 | 0 | 10.4 |
| Ome40 | 50.3 | 1.5 | 8.4 | 36.4 | 0.1 | 10.5 |
| Lan60 | 36.5 | 0.5 | 10.5 | 30.3 | 0.1 | 11.5 |
| Ome20 | 28.3 | 0 | 11.8 | 29.8 | 0 | 11.5 |
| Rab20 | 31.4 | 0.1 | 11.3 | 24.0 | 0 | 12.4 |
| Rab10 | 15.7 | 0.1 | 13.6 | 23.4 | 0.2 | 12.5 |
| Placebo | 0 | 0 | 16 | 0.2 | 0 | 16 |
Eso40, Esomeprazole 40 mg qd; Fex40, Fexuprazan 40 mg qd; Ila10, Ilaprazole 10 mg qd; Kev20, Keverprazan 20 mg qd; Lan30, Lansoprazole 30 mg qd; Lan60, Lansoprazole 60 mg qd; Ome 40, Omeprazole 40 mg qd; Ome 20, Omeprazole 20 mg qd; Pan40, Pantoprazole 40 mg qd; Rab10, Rabeprazole 10 mg bid; Rab20, Rabeprazole 20 mg qd; SUCRA, surface under the cumulative ranking curve; Teg100, Tegoprazan 100 mg qd; Teg50, Tegoprazan 50 mg qd; Vpz20, Vonoprazan 20 mg qd; Vpz40, Vonoprazan 40 mg qd.